Showing results (1-10 of 457) with videos related to
Sort By:
Pageof 46
Rare Cancers and Therapy|May 17, 2016
Bosutinib for Chronic Myeloid LeukemiaMassimo Breccia, Gianni BinottoHematology. American Society of Hematology. Education Program|December 9, 2023
Atypical CML: diagnosis and treatmentMassimo BrecciaCardiovascular & Hematological Disorders Drug Targets|March 12, 2009
Resistance to imatinib in chronic myeloid leukemia and therapeutic approaches to circumvent the problemMassimo Breccia, Giuliana AlimenaCurrent Drug Targets|June 13, 2009
Nilotinib therapy in chronic myelogenous leukemia: the strength of high selectivity on BCR/ABLMassimo Breccia, Giuliana AlimenaExpert Review of Hematology|November 29, 2014
Firstline treatment for chronic phase chronic myeloid leukemia patients should be based on a holistic approachMassimo Breccia, Giuliana AlimenaExpert Review of Molecular Diagnostics|April 3, 2025
Extracellular vesicles as source of biomarkers in hematological malignancies: looking towards clinical applicationsClaudia Ielo, Massimo BrecciaBritish Journal of Haematology|August 4, 2023
Interferon in chronic myeloid leukaemia: Is it useful for treatment-free remission?Massimo Breccia, Giuseppe SaglioCancer Letters|June 12, 2012
Suboptimal response in chronic myeloid leukemia patients treated with imatinib: early identification and new therapeutic challengesMassimo Breccia, Giuliana AlimenaBiodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|May 3, 2011
Activity and safety of dasatinib as second-line treatment or in newly diagnosed chronic phase chronic myeloid leukemia patientsMassimo Breccia, Giuliana AlimenaLeukemia Research|September 29, 2009
Nilotinib: a second-generation tyrosine kinase inhibitor for chronic myeloid leukemiaMassimo Breccia, Giuliana AlimenaPageof 46